0HV.F Envista Holdings Corporation
- Market cap
- EUR 3.66B
- P/E
- 7.0x
- P/B
- 1.32x
- ROE
- 25.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 0HV.F undervalued?
Graham number0HV.F trades 36.2% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Envista Holdings Corporation fundamental analysis
No fundamental analysis for Envista Holdings Corporation yet.
Envista Holdings Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Envista Holdings Corporation
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and period…
Full company profileEnvista Holdings Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Envista Holdings Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.79B | 2.81B | 2.84B | 2.75B | 2.28B | 2.51B | 2.57B | 2.57B | 2.51B | 2.72B | 2.84B |
| Gross Profit | 1.60B | 1.62B | 1.60B | 1.51B | 1.16B | 1.43B | 1.47B | 1.44B | 1.37B | 1.49B | 1.60B |
| Operating Income | 403M | 387M | 298M | 278M | 33.3M | 306M | 319M | 315M | 137M | 236M | 311M |
| EBITDA | - | 508M | 428M | 447M | 196M | 461M | 484M | 171M | -884M | 365M | 1.01B |
| Net Income | 272M | 301M | 231M | 218M | 33.3M | 341M | 243M | -100M | -1.12B | 47.0M | 801M |
| EPS | - | 1.95 | 1.49 | 1.37 | 0.21 | 2.11 | 1.49 | -0.58 | -6.50 | 0.29 | 5.00 |
| Balance Sheet | |||||||||||
| Total Assets | - | 5.99B | 5.84B | 6.16B | 6.88B | 6.57B | 6.59B | 6.61B | 5.35B | 5.68B | 5.61B |
| Total Liabilities | - | 998M | 1.02B | 2.62B | 3.16B | 2.52B | 2.38B | 2.43B | 2.42B | 2.57B | 2.52B |
| Shareholders' Equity | - | 4.99B | 4.82B | 3.54B | 3.72B | 4.06B | 4.21B | 4.17B | 2.93B | 3.11B | 3.09B |
| Cash & Short-term Investments | - | - | - | 211M | 889M | 1.07B | 607M | 940M | 1.07B | 1.21B | 1.16B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 417M | 359M | 400M | 398M | 284M | 362M | 183M | 284M | 337M | 276M | 258M |
| Capital Expenditure | 49.1M | 48.9M | 72.2M | 77.8M | 47.7M | 54.7M | 75.7M | 66.9M | 33.8M | 45.3M | 58.0M |
| Free Cash Flow | - | 310M | 328M | 320M | 236M | 337M | 107M | 217M | 303M | 230M | 200M |
| Ratios | |||||||||||
| ROE | - | 6.0% | 4.8% | 6.1% | 0.9% | 8.4% | 5.8% | -2.4% | -38.1% | 1.5% | 25.9% |
| ROA | - | 5.0% | 3.9% | 3.5% | 0.5% | 5.2% | 3.7% | -1.5% | -20.9% | 0.8% | 14.3% |
| Net Profit Margin | 9.8% | 10.7% | 8.1% | 7.9% | 1.5% | 13.6% | 9.5% | -3.9% | -44.6% | 1.7% | 28.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Envista Holdings Corporation dividends
Envista Holdings Corporation has not paid dividends in the last 9 fiscal years.
Who owns Envista Holdings Corporation
- Insiders 0.56%
- Institutions 99.44%
- Public & others 0.00%
- Shares outstanding 160M
- Free float 160M
Envista Holdings Corporation company profile
- Company name
- Envista Holdings Corporation
- Ticker
- 0HV.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 12,000
- Fiscal year end
- December
- Address
- Building E, Brea, CA, United States, 92821-6208
- Phone
- 714 817 7000
- Website
- envistaco.com
About Envista Holdings Corporation
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products, as well as provides DTX Studio Clinic, a software package offered with its imaging products. This segment offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.
Envista Holdings Corporation management
10- Mr. Paul A. KeelPresident, CEO & Chairman · born 1970
- Mr. Eric D. HammesSenior VP & CFO · born 1975
- Mr. Mark E. Nance J.D.Senior VP, General Counsel & Secretary · born 1969
- Mr. Robert Befidi Jr.Senior VP & President of Diagnostics · born 1975
- Ms. Veronica AcurioSenior VP & President of Orthodontics · born 1971
- Mr. Coree ThomasVP & Chief Accounting Officer · born 1978
- Mr. Andrew ChenChief Information Officer
- Mr. Jim GustafsonVice President of Investor Relations
- Paul SumilasChief Compliance Officer
- Mr. Mischa M. ReisSenior Vice President of Strategy & Corporate Development · born 1973